Introduction: In response to increased workload, cardiomyocytes increase in size, and the heart undergoes hypertrophy. The initial hypertrophy is a compensatory process that adds contractile units but reduces wall stress to help maintain heart function. Yes-associated protein (YAP), a major effector of the Hippo pathway, is transiently activated in response to acute pressure overload (PO). Cardiac-specific heterozygous downregulation of YAP inhibits hypertrophy but promotes heart failure, suggesting that endogenous YAP is salutary and mediates compensatory hypertrophy during the acute phase of PO. However, the mechanism by which YAP mediates compensatory hypertrophy is not well understood. We have shown previously that 3-phosphoglyceric acid and serine accumulate in the heart during acute PO in a YAP-dependent manner. The serine biosynthetic pathway provides precursors for the TCA cycle and antioxidant and purine biosynthesis. Hypothesis: YAP induces serine synthesis, thereby promoting compensatory cardiac hypertrophy in the presence of acute PO. Methods and Results: We evaluated the levels of intermediate enzymes in the serine synthesis pathway in YAP-overexpressing neonatal rat ventricular myocytes (NRVMs). Furthermore, we investigated whether YAP-induced cardiomyocyte hypertrophy is inhibited by siRNA targeting serine biosynthesis enzymes. Immunofluorescent staining of NRVMs with cardiac troponin T was conducted to evaluate cardiomyocyte size, which was assessed using ImageJ software. YAP upregulated protein levels of phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), phosphoserine phosphatase (PSPH), and serine hydroxymethyltransferase 1 (SHMT1) in NRVMs. siRNA-mediated downregulation of PHGDH, PSAT1, PSPH, or SHMT1 significantly inhibited YAP-induced cardiomyocytes hypertrophy. Conclusions: YAP upregulates the expression of enzymes in the serine biosynthesis pathway, thereby inducing hypertrophy in NRVMs. Metabolites of the serine biosynthesis pathway may play an important role in mediating YAP-induced compensatory cardiac hypertrophy.